Apogee Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
APGE Nasdaq 2836 www.apogeetherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Apogee Therapeutics, Inc.

Apogee Therapeutics to Participate in Upcoming June Conferences - May 28th, 2026 2:01 pm
Apogee Therapeutics lines up $1.3B strategic financing for zumilokibart program - May 28th, 2026 12:43 pm
Why Apogee Slipped On Its Dupixent-Rivaling Eczema Results - May 27th, 2026 2:05 pm
Blackstone Backs Apogee With Up To $1.3 Billion - May 27th, 2026 12:33 pm
Apogee Therapeutics Shares Surge Following $1.3 Billion Blackstone Financing Partnership (APOG) - May 27th, 2026 6:06 am
Apogee Therapeutics, Blackstone Life Sciences Enter Financing Collaboration of Up to $1.3 Billion - May 27th, 2026 5:10 am
Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart - May 27th, 2026 4:31 am
Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis - May 27th, 2026 4:30 am
Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026 - May 26th, 2026 2:01 pm
Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results - May 11th, 2026 5:00 am
Apogee Therapeutics Inc. (APGE): Primary Challenger to Established Blockbusters - Apr 27th, 2026 8:05 am
Apogee Therapeutics (APGE) Is Up 17.8% After $403 Million Follow-On Tied To Zumilokibart Data - Mar 27th, 2026 6:16 pm
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million - Mar 26th, 2026 2:01 pm
Apogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for Investors - Mar 26th, 2026 9:53 am
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering - Mar 24th, 2026 7:53 pm
APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy - Mar 24th, 2026 8:26 am
How Apogee, Up 20%, Plans To Take On Rival Regeneron's Eczema Drug - Mar 23rd, 2026 2:06 pm
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering - Mar 23rd, 2026 2:01 pm
Sector Update: Health Care Stocks Advance Late Afternoon - Mar 23rd, 2026 1:54 pm
Top Midday Stories: Trump Orders 5-Day Postponement of Strikes on Iranian Energy Sites; JPMorgan Launches $8 Billion Junk-Bond Sale for EA Buyout - Mar 23rd, 2026 9:26 am